ArticleScience advances2020
In situ recruitment of regulatory T cells promotes donor-specific tolerance in vascularized composite allotransplantation.
Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 59 citations in OpenAlex.
- The Transformative Journey of Vascularized Composite Allotransplantation: Advances, Challenges, and Future Directions.Transplantation direct · 2026Article
- Regulatory T cell attracting therapy accelerates skeletal muscle functional recovery following injury.Scientific reports · 2026Article
- Systematic review of emerging technologies in vascularized composite allotransplantation.Frontiers in transplantation · 2026Review
- Chronic Rejection in Facial Vascularized Composite Allotransplantation (fVCA).Results and problems in cell differentiation · 2026Review
- A review of immunosuppressive therapy in the context of uterine VCA and pregnancy.Frontiers in transplantation · 2026Review
- Uterus transplantation in the United States: analysis of patients and early postoperative outcomes in the national organ procurement and transplantation network.Frontiers in transplantation · 2026Article
- The integration of psychosocial care, ethical governance, and patient-centered research in current and future approaches in the field of vascularized composite allotransplantation.Frontiers in transplantation · 2026Review
- Generating tolerance through in situ recruitment of regulatory T cells for allogeneic cell transplantation in a bioengineered lymphoid platform.Materials today. Bio · 2025Article
- Encapsulation of Therapeutic, Low-Molecular-Weight Chemokines Using a Single Emulsion, Microfluidic, Continuous Manufacturing Process.Pharmaceutics · 2025Article
- Unlocking Transplant Tolerance with Biomaterials.Advanced healthcare materials · 2025Review
- IL-17A-producing γδ T cells and classical monocytes are associated with a rapid alloimmune response following vascularized composite allotransplantation in mice.Frontiers in immunology · 2025Article
- Evaluating the immunogenicity of a mouse partial hindlimb for composite allotransplantation.Frontiers in immunology · 2025Article
- High-affinity chimeric antigen receptor signaling induces an inflammatory program in human regulatory T cells.Molecular therapy. Methods & clinical development · 2024Article
- Lymph Node Inclusion in a Modified Osteomyocutaneous Allograft for Vascularized Composite Allotransplantation: Establishment and Feasibility Assessment in a Pig Model.Plastic and reconstructive surgery. Global open · 2024Article
- Engineering Functional Particles to Modulate T Cell Responses.Accounts of materials research · 2024Article
- Investigation of the Impact of Manufacturing Methods on Protein-Based Long-Acting Injectable Formulations: A Comparative Assessment for Microfluidics vs. Conventional Methods.Pharmaceutics · 2024Article
- Identification and Characterization of Critical Processing Parameters in the Fabrication of Double-Emulsion Poly(lactic-co-glycolic) Acid Microparticles.Pharmaceutics · 2024Article
- High affinity chimeric antigen receptor signaling induces an inflammatory program in human regulatory T cells.bioRxiv : the preprint server for biology · 2024Article
- Immunogenicity and tolerance induction in vascularized composite allotransplantation.Frontiers in transplantation · 2024Review
- Clinical Manufacturing of Regulatory T Cell Products For Adoptive Cell Therapy and Strategies to Improve Therapeutic Efficacy.Organogenesis · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
Vascularized composite allotransplantation (VCA) encompasses face and limb transplantation, but as with organ transplantation, it requires lifelong regimens of immunosuppressive drugs to prevent rejection. To achieve donor-specific immune tolerance and reduce the need for systemic immunosuppression, we developed a synthetic drug delivery system that mimics a strategy our bodies naturally use to recruit regulatory T cells (T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.